DR. MARTENS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 72.7 GBX | +1.89% |
|
+8.02% | -17.95% |
| Apr. 26 | Peel Hunt cuts ConvaTec to 'reduce' | AN |
| Apr. 22 | Jefferies Cuts Dr. Martens PT, Keeps Sector Perform Rating | MT |
Valuation
| Fiscal Period: Maart | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 4,532 | 2,388 | 1,424 | 699.3 | - | - |
| Enterprise Value (EV) 1 | 4,706 | 2,554 | 1,712 | 1,018 | 1,008 | 991.6 |
| P/E ratio | 126 x | 13.2 x | 11 x | 10.1 x | 18 x | 11.8 x |
| Yield | - | 2.3% | 4.1% | 8.02% | 5.54% | 5.35% |
| Capitalization / Revenue | 5.86 x | 2.63 x | 1.42 x | 0.79 x | 0.82 x | 0.77 x |
| EV / Revenue | 6.09 x | 2.81 x | 1.71 x | 1.14 x | 1.19 x | 1.1 x |
| EV / EBITDA | 21 x | 9.71 x | 6.99 x | 5.15 x | 6.55 x | 5.25 x |
| EV / FCF | 27.7 x | 19.3 x | 66.1 x | 20.2 x | 13.3 x | 13.6 x |
| FCF Yield | 3.61% | 5.17% | 1.51% | 4.95% | 7.52% | 7.34% |
| Price to Book | 30.1 x | 7.3 x | 3.52 x | 1.74 x | 1.77 x | 1.63 x |
| Nbr of stocks (in thousands) | 1,000,000 | 1,000,111 | 1,000,770 | 961,879 | - | - |
| Reference price 2 | 4.532 | 2.388 | 1.423 | 0.7270 | 0.7270 | 0.7270 |
| Announcement Date | 6/17/21 | 6/1/22 | 6/1/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 672.2 | 773 | 908.3 | 1,000 | 890 | 849.1 | 904.8 |
| EBITDA 1 | - | 224.2 | 263 | 245 | 197.6 | 153.8 | 188.8 |
| EBIT 1 | - | 193 | 229.3 | 176.2 | 125.6 | 77.49 | 111.1 |
| Operating Margin | - | 24.97% | 25.24% | 17.61% | 14.12% | 9.13% | 12.28% |
| Earnings before Tax (EBT) 1 | - | 70.9 | 214.3 | 159.4 | 94.8 | 54.85 | 79 |
| Net income 1 | 74.8 | 35.7 | 181.2 | 128.9 | 69.07 | 40.42 | 49.53 |
| Net margin | 11.13% | 4.62% | 19.95% | 12.89% | 7.76% | 4.76% | 5.47% |
| EPS 2 | - | 0.0360 | 0.1810 | 0.1290 | 0.0720 | 0.0403 | 0.0616 |
| Free Cash Flow 1 | - | 169.8 | 132.1 | 25.9 | 50.35 | 75.8 | 72.75 |
| FCF margin | - | 21.97% | 14.54% | 2.59% | 5.66% | 8.93% | 8.04% |
| FCF Conversion (EBITDA) | - | 75.74% | 50.23% | 10.57% | 25.48% | 49.28% | 38.53% |
| FCF Conversion (Net income) | - | 475.63% | 72.9% | 20.09% | 72.9% | 187.51% | 146.87% |
| Dividend per Share 2 | - | - | 0.0550 | 0.0584 | 0.0583 | 0.0403 | 0.0389 |
| Announcement Date | 10/2/20 | 6/17/21 | 6/1/22 | 6/1/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 Q4 | 2024 S2 | 2025 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 454.8 | 369.9 | 538.4 | 418.6 | 581.7 | 395.8 | 213 | 486.9 | - |
| EBITDA | - | 88.8 | - | 88.8 | - | 77.6 | - | 116 | - |
| EBIT | - | - | - | - | - | 40.3 | - | - | 1.6 |
| Operating Margin | - | - | - | - | - | 10.18% | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | 25.8 | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | 0.0190 | - | 0.0550 | - |
| Dividend per Share | - | - | - | - | - | 0.0156 | - | - | - |
| Announcement Date | 6/17/21 | 12/9/21 | 6/1/22 | 11/24/22 | 6/1/23 | 11/30/23 | - | - | - |
1GBP in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 174 | 166 | 288 | 319 | 309 | 292 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 0.7756 x | 0.6304 x | 1.177 x | 1.612 x | 2.007 x | 1.548 x |
| Free Cash Flow 1 | - | 170 | 132 | 25.9 | 50.4 | 75.8 | 72.8 |
| ROE (net income / shareholders' equity) | - | 105% | 75.8% | 35.2% | 17.4% | 7.18% | 15.9% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 0.1500 | 0.3300 | 0.4000 | 0.4200 | 0.4100 | 0.4500 |
| Cash Flow per Share 2 | - | 0.1600 | 0.1800 | 0.0800 | 0.1300 | 0.1500 | 0.1600 |
| Capex 1 | - | 18.6 | 25 | 51.4 | 51 | 52 | 53.3 |
| Capex / Sales | - | 2.41% | 2.75% | 5.14% | 5.73% | 6.12% | 5.89% |
| Announcement Date | 10/2/20 | 6/17/21 | 6/1/22 | 6/1/23 | - | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
0.727
GBP
Average target price
0.7927
GBP
Spread / Average Target
+9.04%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.95% | 871M | |
| +24.69% | 21.39B | |
| +21.58% | 10.31B | |
| -6.73% | 8.54B | |
| +34.25% | 7.61B | |
| -13.48% | 6.99B | |
| +16.67% | 3.26B | |
| +65.97% | 2.95B | |
| -8.00% | 2.48B | |
| -17.43% | 2.1B |
- Stock Market
- Equities
- DOCS Stock
- Financials Dr. Martens plc
